News & Trends - Pharmaceuticals

Novartis’ new drug – an attractive option in AMD treatment

Health Industry Hub | February 5, 2020 |
[Total: 1    Average: 4/5]

Novartis announced that the Therapeutic Goods Administration (TGA) registered Beovu (brolucizumab) solution for injection for the treatment of wet (neovascular) age-related macular degeneration (nAMD).

Beovu is the first approved anti-vascular endothelial growth factor (anti-VEGF) in Australia to offer the ability to maintain wet AMD patients on a three-month dosing interval.

In two head-to-head clinical trials, Phase III HAWK and HARRIER, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to
Bayer’s Eylea (aflibercept) at year one with superior anatomic outcomes in retinal fluid, retinal thickness and reduced disease activity.

Considering Eylea’s success to date, Novartis’ Beovu is bound to be an attractive drug for ophthalmologists to reduce injection frequency and enhance patient adherence once PBS reimbursement is secured.

Frequent administration has been a long-standing issue associated with the otherwise effective anti-VEGF injections for patients with wet AMD. Novartis’ anti-VEGF, Lucentis (ranibizumab) is injected into the eye every four weeks according to the label, while Bayer’s Eylea (aflibercept) is approved for intravitreal (IVT) injection every four or every eight weeks.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

“We look forward to accessing this drug to treat our patients with wet age-related macular degeneration which is a leading cause of blindness in Australia.” said Associate Clinical Professor of Sydney University and Vitreoretinal Ophthalmologist and Surgeon, Dr. Andrew Chang.

Macular Disease Foundation Australia CEO, Dee Hopkins said: “We hope that real world outcomes will result in reduced treatment burden on patients and improve persistence rates for sight saving treatment.”

“Beovu is a testament to our commitment here at Novartis to reimagine medicine for patients living with wet age-related macular degeneration” said Richard Tew, General Manager of Novartis Pharmaceuticals Australia and New Zealand. “We are delighted that Beovu is now registered in Australia.”

Wet age-related macular degeneration (wet AMD) is a chronic, degenerative eye disease affecting approximately 133,000 Australians.

In November 2019 the PBAC did not recommend Beovu for the treatment of patients with wet AMD, based on Novartis’ first submission.

Novartis is committed to ensuring patient access to Beovu and will work closely with all stakeholders to help improve the lives of Australians living with eye diseases.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. Health Industry Hub is the only one-stop-hub connecting Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with our proven digital media solutions developed by industry for industry.

You may also like Arrotex boosts respiratory portfolio to $263m with new Boehringer Ingelheim partnership

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Pharmaceuticals

First immunotherapy PBS listed in small cell lung cancer - Pharma News

First immunotherapy treatment PBS listed in small cell lung cancer

Health Industry Hub | February 19, 2020 |

Pharma News: Effective 1 March 2020 the first immunotherapy treatment for small cell lung cancer (SCLC) will be available on […]


News & Trends - Medical Technology

Blood test to improve ovarian cancer diagnosis - MedTech News

Blood test to improve ovarian cancer diagnosis

Health Industry Hub | February 19, 2020 |

MedTech News: Australian researchers have developed a simple blood test that measures the body’s own immune response to improve diagnosis […]



The largest healthcare event in the region - Australian Healthcare Week - Medical News

Don’t miss the largest healthcare event in the region – Australian Healthcare Week

Health Industry Hub | February 19, 2020 |

Health Industry Hub is proud to partner with and support the free-to-attend 10th Annual Australian Healthcare Week Expo, held March […]


News & Trends - Pharmaceuticals

BMS announces new 5-year data in advanced renal cell carcinoma - Pharma News

BMS announces new 5-year data in advanced renal cell carcinoma

Health Industry Hub | February 19, 2020 |

Pharma News: Bristol-Myers Squibb announced five-year follow-up study results demonstrating that Opdivo (nivolumab) treatment delivers superior overall survival (OS) and […]